Multiple Sclerosis info
No formal drug interaction studies have been conducted with Rebif ®.
Due to its potential to cause neutropenia and lymphopenia, proper monitoring of patients is required if Rebif ® is given in combination with myelosuppresive agents.
In identical twins where one twin develops the disease, the likelihood of the second twin developing Multiple Sclerosis is approx 30%.
Life expectancy for people who have multiple sclerosis is growing longer with every passing year, particularly with the advancement of medical science, new drugs and better care and understanding of the disease.... Read More
Send mail to web(at)themcfox.com with questions or comments about this web site.
Welcome to the new look site.